儿童紫贝宣肺糖浆治疗急性气管支气管炎(风热犯肺证)的随机双盲多中心对照试验
该研究为年龄分层、区组随机、双盲、极低剂量平行对照的多中心临床试验,纳入453例急性气管支气管炎风热犯肺证患儿,按3:1随机分为儿童紫贝宣肺糖浆组与极低剂量对照组。主要结局为给药7天后咳嗽VAS评分下降值,试验组显著优于对照组(6.35±3.45 vs 3.73±3.98,p<0.001),中医证候总评分有效率亦显著提高,不良反应两组无显著差异。
要点
- 儿童紫贝宣肺糖浆可显著改善风热犯肺证急性气管支气管炎患儿的咳嗽VAS评分。
- 7天中医证候总评分有效率试验组91.38% vs 对照组54.95%(p<0.001)。
- 不良反应两组无显著差异(17.82% vs 13.51%,P>0.05)。
核心结论
- 儿童紫贝宣肺糖浆治疗儿童急性气管支气管炎风热犯肺证可能非常有效且安全。
- 未来需大样本研究收集更多儿童安全性数据。
研究设计与样本
- 采用年龄分层、区组随机、双盲、极低剂量平行对照、多中心临床试验设计。
- 共纳入453例西医诊断为急性气管支气管炎、中医辨证为外感咳嗽风热犯肺证的患儿。
- 按年龄1~3岁、4~7岁、8~14岁分层,以3:1比例随机分配至儿童紫贝宣肺糖浆组和极低剂量儿童紫贝宣肺糖浆对照组。
- 主要结局为给药7天后咳嗽视觉模拟量表(VAS)评分下降值。
主要发现
- 两组服药依从性高(完成率>80%):试验组299/323(92.6%),对照组103/107(96.3%),p>0.05。
- 给药7天后咳嗽VAS评分下降值试验组显著优于对照组(6.35±3.45 vs 3.73±3.98,p<0.001)。
- 年龄亚组分析:1-3岁组5.80±3.43 vs 3.75±4.38(P=0.003);4-7岁组6.30±3.69 vs 2.73±3.65(P<0.001);8-14岁组6.91±3.12 vs 4.69±3.75(P=0.001)。
- 给药5天后咳嗽VAS评分下降值试验组 vs 对照组为5.88±2.90 vs 3.55±3.41(P<0.001);给药3天后为3.61±2.53 vs 2.43±2.56(P<0.001)。
- 中医证候总评分有效率:给药7天后91.38% vs 54.95%,5天后86.93% vs 50.94%,3天后64.78% vs 40.19%(各p<0.001)。
关键数值与推荐
- 主要结局指标为给药7天后咳嗽VAS评分下降值,试验组6.35±3.45,对照组3.73±3.98,p<0.001。
- 中医证候总评分有效率在给药7天后为91.38% vs 54.95%(p<0.001)。
- 不良反应发生率两组无显著差异(59/331,17.82% vs 15/111,13.51%,P>0.05)。
- 试验组发生5例严重不良事件(发生率1.21%),均与试验药物无关。
临床怎么用
- 对于儿童急性气管支气管炎风热犯肺证,可考虑使用儿童紫贝宣肺糖浆以改善咳嗽症状和中医证候。
- 用药7天可观察到咳嗽VAS评分和中医证候总评分的显著改善。
- 使用过程中需关注不良反应,严重不良事件虽与药物无关,但仍需监测。
局限性
- 未来仍需大样本研究收集更多儿童安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Children's Zibei Xuanfei syrup is an herbal preparation from a lifetime professor, famous old Chinese doctor, and postgraduate supervisor of medical doctor of Shandong University of Traditional Chinese Medicine. This herbal preparation promotes lung health, relieves cough, reduces phlegm, and benefits pharynx. AIM OF THE STUDY: To verify the clinical efficacy and safety of Zibei Xuanfei syrup for children in treatment of acute trachea bronchitis with wind-heat invading lung syndrome. MATERIALS AND METHODS: This was an age-stratified, block randomized, double-blind, extremely low dose parallel control, multi-center clinical trial. A total of 453 pediatric patients diagnosed with acute tracheal bronchitis in Western medicine and cough due to exogenous factors with wind-heat invading lung syndrome in Chinese medicine were enrolled. They were divided into three subgroups based on age 1∼3, 4-7, and 8-14 years old, and randomly assigned to children's Zibei Xuanfei syrup and extremely low doses of children's Zibei Xuanfei syrup (control) in a 3:1 ratio. The primary outcome was the decreased values of cough Visual Analogue Scale (VAS) score after 7 days of administration. Secondary outcomes included a decrease in cough VAS score after 3 and 5 days of the administration, and the total score of Traditional Chinese Medicine(TCM) syndrome after 3, 5, and 7 days of treatment. The chest X-ray and blood C-reactive protein were examined during screening. The safety assessment included blood urine, and stool routine, liver and kidney function of laboratory tests, and an electrocardiogram at the screening and the last visit. RESULTS: The subjects of two groups had high administration adherence (completion over 80%) (299/323, 92.6% in children's Zibei Xuanfei syrup group vs 103/107, 96.3% in the control group; p > 0.05). The children's Zibei Xuanfei syrup group was significantly better than the control group in the decreased values of cough VAS score after 7 days of administration(6.35 ± 3.45 vs 3.73 ± 3.98, p < 0.001). The subgroup analysis of the decreased value of cough VAS scores aged 1-3 years old were 5.80 ± 3.43 vs 3.75 ± 4.38 (P = 0.003), 4-7 years old was 6.30 ± 3.69 vs 2.73 ± 3.65 (P < 0.001), and 8-14 years old were 6.91 ± 3.12 vs 4.69 ± 3.75(P = 0.001)respectively. The secondary outcomes decrease values of cough VAS score of children's Zibei Xuanfei syrup group vs control group after 5 days of administration were 5.88 ± 2.90 vs 3.55 ± 3.41(P < 0.001), after 3 days of administration were 3.61 ± 2.53 vs 2.43 ± 2.56 (P < 0.001). The effective rate of the TCM symptom total score of children's Zibei Xuanfei syrup group vs control group was 91.38% vs 54.95%after 7 days of the administration, 86.93% vs 50.94% after 5 days of the administration, and 64.78% vs 40.19% after 3 days administration(each p < 0.001). There was no significant difference in Adverse Event between the two groups (59/331, 17.82% vs 15/111, 13.51%, P > 0.05). The children's Zibei Xuanfei syrup group had 5 Serious Adverse Events (incidence rate 1.21%), all of which were unrelated to the trial drug. CONCLUSION: Children's Zibei Xuanfei syrup appears to be extremely effective and safe in the treatment of acute trachea bronchitis with wind-heat invading lung syndrome. Future studies with large sample sizes will need to collect more safety data use for children.
引用
- Chen HF, Song GH, Zhao G, et al. Efficacy and safety of Chinese herbal medicine children's Zibei Xuanfei syrup in treating acute trachea-bronchitis with wind-heat invading lung syndrome: A randomized, double-blind, multicentre, controlled trial. J Ethnopharmacol. 2023. PMID: 36736712. doi:10.1016/j.jep.2023.116207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。